EGFR and MET — Drug Target

All drugs that target EGFR and MET — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

Tyrosine kinase inhibitor combination · Bispecific monoclonal antibody · PD-1 inhibitor

Phase 3 pipeline (2)

• Savolitinib + Osimertinib · Hutchison Medipharma Limited · Tyrosine kinase inhibitor combination · Oncology
  Savolitinib and osimertinib together target MET and EGFR pathways to overcome resistance in lung cancer.
• Amivantamab Intravenous · Janssen Research & Development, LLC · Bispecific monoclonal antibody · Oncology
  Amivantamab is a bispecific monoclonal antibody that simultaneously binds to EGFR and MET receptors, blocking their signaling and triggering immune-mediated tumor cell death.

Phase 2 pipeline (1)

• Amivantamab SC · Janssen Research & Development, LLC · PD-1 inhibitor · Oncology
  Amivantamab SC is a fully human bispecific antibody that targets and blocks the activity of the EGFR and MET receptors.